Baxter Declares Quarterly Dividend
Baxter International (NYSE:BAX) has declared a quarterly cash dividend of $0.17 per share of common stock, payable on Jan. 2, 2025, to stockholders of record as of Nov. 29, 2024. The indicated annual dividend rate is $0.68 per share. This new quarterly dividend rate is set in anticipation of the Kidney Care business segment divestiture to Carlyle, expected to close in late 2024 or early 2025. The dividend targets a payout ratio of approximately 25% of adjusted net income, aligning with peer companies. Baxter maintains its 93-year history of consistent dividend payments while balancing business reinvestment with shareholder returns.
Baxter International (NYSE:BAX) ha dichiarato un dividendo in contanti trimestrale di $0,17 per azione di azioni ordinarie, che sarà pagato il 2 gennaio 2025, agli azionisti registrati al 29 novembre 2024. Il tasso di dividendo annuale indicato è di $0,68 per azione. Questo nuovo tasso di dividendo trimestrale è stato stabilito in previsione della cessione del segmento Kidney Care a Carlyle, che dovrebbe concludersi entro la fine del 2024 o all'inizio del 2025. Il dividendo mira a un rapporto di distribuzione di circa il 25% del reddito netto rettificato, allineandosi con le aziende concorrenti. Baxter continua la sua storia di 93 anni di pagamenti di dividendi costanti, bilanciando il reinvestimento aziendale con i ritorni per gli azionisti.
Baxter International (NYSE:BAX) ha declarado un dividendo en efectivo trimestral de $0,17 por acción de acciones ordinarias, que se pagará el 2 de enero de 2025, a los accionistas registrados al 29 de noviembre de 2024. La tasa anual de dividendo indicada es de $0,68 por acción. Esta nueva tasa de dividendo trimestral se establece en anticipación de la desinversión del segmento Kidney Care a Carlyle, que se espera se cierre a finales de 2024 o principios de 2025. El dividendo tiene como objetivo una relación de pago de aproximadamente el 25% de los ingresos netos ajustados, alineándose con las empresas competidoras. Baxter mantiene su historia de 93 años de pagos de dividendos consistentes mientras equilibra la reinversión empresarial con los retornos a los accionistas.
백스터 인터내셔널 (NYSE:BAX)가 주당 $0.17의 현금 배당금을 분기별로 선언하였으며, 이는 2025년 1월 2일에 현금배당을 실시합니다. 배당금 지급 기준일은 2024년 11월 29일입니다. 연간 배당금율은 주당 $0.68입니다. 이 새로운 분기 배당금율은 신장 관리 사업 부문 매각을 카라이엘에 양도하는 것에 대한 예상에 따라 설정되었습니다. 이 매각은 2024년 말 또는 2025년 초에 마무리될 예정입니다. 배당금은 조정된 순이익의 약 25%에 해당하는 지급 비율을 목표로 하며, 동종 기업들과 일치합니다. 백스터는 93년간의 이consistent한 배당금 지급 내역을 유지하며, 사업 재투자와 주주 수익 간의 균형을 맞추고 있습니다.
Baxter International (NYSE:BAX) a déclaré un dividende trimestriel en espèces de 0,17 $ par action d'actions ordinaires, payable le 2 janvier 2025, aux actionnaires inscrits au 29 novembre 2024. Le taux de dividende annuel indiqué est de 0,68 $ par action. Ce nouveau taux de dividende trimestriel est établi en prévision de la cession du segment Kidney Care à Carlyle, qui devrait se conclure fin 2024 ou début 2025. Le dividende vise un ratio de distribution d'environ 25 % du revenu net ajusté, s'alignant ainsi avec les entreprises concurrentes. Baxter maintient son histoire de 93 ans de paiements de dividendes constants tout en équilibrant le réinvestissement dans l'entreprise et les rendements pour les actionnaires.
Baxter International (NYSE:BAX) hat eine vierteljährliche Dividende von $0,17 pro Aktie auf Stammaktien erklärt, die am 2. Januar 2025 an die Aktionäre, die am 29. November 2024 im Aktienregister stehen, ausgezahlt wird. Der angegebene jährliche Dividendenbetrag beträgt $0,68 pro Aktie. Diese neue vierteljährliche Dividende wird in Erwartung der Veräußerrung des Geschäftsbereichs Kidney Care an Carlyle festgelegt, die voraussichtlich Ende 2024 oder Anfang 2025 abgeschlossen wird. Die Dividende strebt ein Ausschüttungsverhältnis von etwa 25 % des adjustierten Nettoeinkommens an, was mit Wettbewerbern übereinstimmt. Baxter bewahrt seine 93-jährige Geschichte konsistenter Dividendenzahlungen und balanciert dabei die Reinvestition in das Unternehmen mit den Renditen für die Aktionäre.
- 93-year track record of consistent dividend payments
- Maintains 25% payout ratio of adjusted net income
- Strategic divestiture of Kidney Care segment to enhance focus
- Reduced dividend rate following Kidney Care divestiture
This dividend represents the new quarterly dividend rate for Baxter in anticipation of the divestiture of its Kidney Care business segment to
“This quarterly dividend targets a payout ratio of approximately
About Baxter
Every day, millions of patients, caregivers and healthcare providers rely on Baxter's leading portfolio of diagnostic, critical care, kidney care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For more than 90 years, we've been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers who make it happen. With products, digital health solutions and therapies available in more than 100 countries, Baxter's employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit www.baxter.com and follow us on X, LinkedIn and Facebook.
This release includes forward-looking statements concerning the company’s capital allocation, which currently includes the issuance of quarterly dividends, and the pending sale of the Kidney Care business (including the expected timeframe for completing the proposed transaction). These forward-looking statements are based on assumptions about many factors (including Baxter’s ability to achieve its short- and long-term financial goals, including after giving effect to the pending Kidney Care sale), and it is possible that Baxter’s annual dividend payout rate may differ, possibly materially, from the anticipated annual indicative dividend described herein or may be suspended for a period of time. For information about some of the risks and important factors that could affect Baxter’s future results, financial condition and liquidity, see Baxter’s most recent filings on Forms 10-K and 10-Q and other SEC filings, all of which are available on Baxter’s website. Baxter does not undertake to update its forward-looking statements unless otherwise required by the federal securities laws.
Baxter is a registered trademark of Baxter International Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241111890466/en/
Media Contact
Steve Brett, (224) 948-5353
media@baxter.com
Investor Contact
Clare Trachtman, (224) 948-3020
Source: Baxter International Inc.
FAQ
What is Baxter's (BAX) new quarterly dividend amount for 2025?
When will Baxter (BAX) pay its next dividend?
What is Baxter's (BAX) annual dividend rate for 2025?